Access Pharmaceuticals, Inc.

Third oral drug delivery research deal announced

Published in Nursing Home and Elder Business Week, June 19th, 2005

Access Pharmaceuticals, Inc., (AKC) announced that it has commenced a third oral drug delivery research collaboration.

This collaboration is aimed at combining Access' proprietary vitamin B12 oral drug delivery technology with the potential Alzheimer disease treatment drug, Oligotropin (HF0420) owned by U.K.-based biopharmaceutical company Hunter-Fleming, Ltd.

The vitamin B12 oral drug delivery technology utilizes the body's natural transport system for vitamin B12. This receptor-mediated process actively transports vitamin B12 from the gut to the blood stream. Access' scientists have found that the attachment of vitamin B12 to drugs, polymers...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Nursing Home and Elder Business Week

Source: Nursing Home and Elder Business Week (2005-06-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry